Business Wire

Bloom Energy Enters Northern European Markets with New Sales Agreement

27.4.2023 16:15:00 EEST | Business Wire | Press release

Share

Bloom Energy (NYSE:BE) has signed an agreement with Elugie to provide a total of 9.75 megawatts (MW) of power from the Bloom Energy Server® at five commercial, industrial and data center sites in Belgium. It is Bloom’s first entry to the northern Europe market. Elugie, which has its headquarters in Riga, Latvia, with offices in Mechelen, Belgium, is an energy service company in the Benelux market of Belgium, the Netherlands and Luxembourg.

Bloom’s solid-oxide fuel cell platforms, to be delivered in late 2023 and early 2024, will include Bloom’s new compatibility with Combined Heat and Power (CHP) systems. Elugie and Bloom are in discussions about deploying additional Bloom energy platforms to sites in the Netherlands and the Baltic nations, comprised of Latvia, Lithuania and Estonia. Elugie is also in discussions with Bloom about the opportunity to deploy the hydrogen-producing Bloom Electrolyzer™.

The agreement with Elugie is another major step in Bloom’s expansion into Europe, following marketing partnership agreements with Telam for Spain and Portugal announced earlier this year, and energy platform sales to Cefla and Ferrari in Italy announced in 2022. It will be the largest deployment of Bloom’s new CHP feature, which is an important energy efficiency and climate-friendly technology for industrial and commercial electricity users in Europe.

“This is a big win in support of our focus to build international business sales,” said Tim Schweikert, Senior Managing Director of International Business Development, Bloom Energy. “We look forward to Elugie’s work in Belgium and the many markets that it serves. This builds on our activities to grow sales across Europe and also in target markets in Asia.”

“Elugie is proud of developing opportunities with Bloom for a total capacity of 9.75MW in Belgium,” says Bjorn Van Haver, founder, Elugie. “This partnership will bring utility-scale clean solutions to critical customers in the country. Our objective is also to deploy Bloom’s servers in the Netherlands and the Baltics. Elugie is an experienced EPC (engineering, procurement and construction company) in delivering energy-as-a-service.”

For more information about Bloom Energy’s CHP technology visit:
https://www.bloomenergy.com/applications/energy-server-with-heat-capture/

Forward-Looking Statements
This press release contains certain forward-looking statements that are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “will” and “would” or the negative of these words or similar terms or expressions that concern Bloom’s expectations, strategy, priorities, plans or intentions. These forward-looking statements include, but are not limited to: Bloom’s expectations regarding collaboration with Elugie and/or its customers; any expected features, such as CHP, or benefits from or the size of the collaboration with Elugie or installations in northern Europe; Bloom’s international expansion plans; and Bloom’s long-term commitment to particular regions, policies or imperatives. More information on potential risks and uncertainties that may impact Bloom’s business are set forth in Bloom’s periodic reports filed with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on February 21, 2023 as well as subsequent reports filed with or furnished to the SEC from time to time. Bloom assumes no obligation to, and does not currently intend to, update any such forward-looking statements.

About Bloom Energy
Bloom Energy empowers businesses and communities to responsibly take charge of their energy. The company’s leading solid oxide platform for distributed generation of electricity and hydrogen is changing the future of energy. Fortune 100 companies around the world turn to Bloom Energy as a trusted partner to deliver lower carbon energy today and a net-zero future. For the latest news and announcements on Bloom Energy, visit https://newsroom.bloomenergy.com/.

For more information on Bloom Energy, visit https://www.bloomenergy.com/.

About Elugie
Since 2000, Elugie founder Bjorn Van Haver has been striving for a sustainable energy transition, for this and future generations. Elugie a pioneer in hydrogen power stations, where hydrogen is ingeniously converted into socially responsible electricity for buildings: more sustainable, smarter, more efficient, cheaper and autonomous from the grid. Elugie is renting power stations connected to the Elugie smart grid platform and green gas contracts. Elugie’s mission is to reduce costs, reduce carbon and maximize efficiency in compliance with the European Union taxonomy for sustainable activities. For more information, visit www.Elugie.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Bloom Energy Media Contact:
Virginia Citrano
press@bloomenergy.com

Bloom Energy Investor Relations:
Ed Vallejo
267.370.9717
Edward.Vallejo@bloomenergy.com

Elugie Media Contact:
Bjorn Van Haver
info@elugie.be

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive

emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release

emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead

Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release

Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme

EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release

European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea

ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release

ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye